The short version
Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $143.33 per unit over the past year.
Market view
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide · Tablet
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 150 mg; 150 mg; 200 mg; TENOFOVIR ALAFENAMIDE FUMARATE 10 mg · Tablet · #30 tablets/bottle, plastic
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $143.33 · middle half $143.33–$143.33 · full range $143.33–$143.33 · 1 products · 1 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- GenvoyaAug 19, 2026Price upNADAC $143.31288 → $143.32827 per unit (+0.01%)
- GenvoyaJul 29, 2026Mfr exitedGilead Sciences, Inc. · elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
- GenvoyaJul 22, 2026Price downNADAC $143.34972 → $143.31288 per unit (-0.03%)
- GenvoyaJul 22, 2026Mfr enteredGilead Sciences, Inc. · elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Same drug class
Other molecules FDA puts in Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- abacavir sulfate, dolutegravir sodium, lamivudine· 1 maker
- dolutegravir sodium and lamivudine· 1 maker
- dolutegravir sodium and rilpivirine hydrochloride· 2 makers
- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate· 2 makers
- cabotegravir sodium· 5 makers
- raltegravir· 7 makers
- dolutegravir sodium· 13 makers
Common questions
- Is Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in shortage right now?
- No. FDA does not currently list Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide?
- 1 company has marketed Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide cost?
- The typical pharmacy pays about $143.33 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.